Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Another big boost to India's vaccination drive as Zydus&nbsp;Cadila&nbsp;gears to launch ZyCov-D, the world&rsquo;s first DNA vaccine against Covid-19 , in October. Reports indicate that Zydus&nbsp;has pegged the price of the bloodless jab at Rs 1900 per shot and the government is negotiating to reduce it to more affordable levels.&nbsp;Read/Watch Also: Meet Zycov-D, how it works and how efficient is it?ZyCov-D is the first DNA-based and needle-free vaccine, its price range, compared to other jabs, is set to be higher. The special applicator that the vaccine requires costs Rs 35,000, driving up the price range of the vaccine dose.
The vaccine will be the first in India to be administered to children in the age groups of 12-18 years. The three doses of the ZyCoV-D vaccine will be administered on day 0, day 28 and day 56.


Zydus Cadila's Zycov D to cost Rs 1900, vaccine for kids to be available in October: reports

India's first covid vaccine for kids above 12 and the world's first DNA based vaccine to be available from October 

Zycov D: Vaccine for kids to be rolled out in October in India

Use of pricey and complex gun &amp; applicator mechanism, driving up the jab's cost for&nbsp;Zydus Cadila's ZyCoV-D vaccine

Another big boost to India's vaccination drive as Zydus&nbsp;Cadila&nbsp;gears to launch ZyCov-D, the world&rsquo;s first DNA vaccine against Covid-19 , in October. Reports indicate that Zydus&nbsp;has pegged the price of the bloodless jab at Rs 1900 per shot and the government is negotiating to reduce it to more affordable levels.&nbsp; Read/Watch Also: <a href="https://www.editorji.com/story/meet-zycov-d-the-world-s-first-dna-covid-19-vaccine-everything-you-need-to-know-about-the-new-vaccine-1629658709134">Meet Zycov-D, how it works and how efficient is it?</a> ZyCov-D is the first DNA-based and needle-free vaccine, its price range, compared to other jabs, is set to be higher. The special applicator that the vaccine requires costs Rs 35,000, driving up the price range of the vaccine dose.
The vaccine will be the first in India to be administered to children in the age groups of 12-18 years. The three doses of the ZyCoV-D vaccine will be administered on day 0, day 28 and day 56.

Zydus Cadila on Friday said that the company plans to make five crore doses of its Covid-19 vaccine by the end of this year, and looking to further scale it up. At present, its vaccine candidate is in the phase 3 clinical trial in India. Zydus Cadila was the second Indian company to receive an approval to start vaccine trial in the country.
Dubbed as ZyCoV-D, it will be the first Made-in-India DNA vaccine candidate against coronavirus. The drugmaker will submit the trial results to the regulator by the end of this month. 
Sharvil Patel, managing director (MD) of Zydus Group told CNBC TV18 in an interview, that they are still on track for May-end submission to the drug regulator once they have trial data about the efficacy of the drug, following which they will file for an emergency use authorisation.

Zydus Cadila to produce 5 crore Covid vaccine doses by year-end

Zydus Cadila&nbsp;plans to produce 5 crore Covid vaccine doses by year-end, will send trial results to regulator soon

Zydus Cadila&nbsp;plans to make 5 crore&nbsp;vaccine doses by December
Zydus' vaccine candidate currently in phase 3 clinical trials
Zydus Cadila was the second Indian firm to get approval
ZyCoV-D will be the first made-in-India DNA vaccine
Drugmaker will submit trial results to DCGI&nbsp;by end of month
&nbsp;

Zydus Cadila on Friday said that the company plans to make five crore doses of its Covid-19 vaccine by the end of this year, and looking to further scale it up. At present, its vaccine candidate is in the phase 3 clinical trial in India. Zydus Cadila was the second Indian company to receive an approval to start vaccine trial in the country.
Dubbed as ZyCoV-D, it will be the first Made-in-India DNA vaccine candidate against coronavirus. The drugmaker will submit the trial results to the regulator by the end of this month. 
Sharvil Patel, managing director (MD) of Zydus Group told CNBC TV18 in an interview, that they are still on track for May-end submission to the drug regulator once they have trial data about the efficacy of the drug, following which they will file for an emergency use authorisation.

Covaxin, Bharat Biotech's vaccine, cleared for Phase 3 trials

Covaxin, the coronavirus vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), has been cleared for the third phase of clinical trials.
The Hyderabad-based vaccine maker had applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission.
The study would cover 28,500 subjects above the age of 18, and would be conducted in 19 sites - including Delhi, Mumbai, Patna and Lucknow.
Besides, Bharat Biotech, an indigenously developed vaccine candidate by Zydus Cadila Ltd is also in Phase 2 of human clinical trials.

Covaxin & Bharat Biotech's vaccine, cleared for Phase 3 trials

Covaxin, the coronavirus vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), has been cleared for the third phase of clinical trials.
The Hyderabad-based vaccine maker had applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission.
The study would cover 28,500 subjects above the age of 18, and would be conducted in 19 sites - including Delhi, Mumbai, Patna and Lucknow.
Besides, Bharat Biotech, an indigenously developed vaccine candidate by Zydus Cadila Ltd is also in Phase 2 of human clinical trials.

zydus cadila ltd

Categories